ImmunoGen Inc. (NASDAQ:IMGN) finished Thursday with a subtraction of -$0.29 to close at $14.09, a downside of -2.02 percent. An average of 8,149,520 shares of common stock have been traded in the last five days. There was a fall of -$2.49 in the past week, and it reached a new high 22 times over the past 12 months. The last 20 days have seen an average of 6,011,235 shares traded, while the 50-day average volume stands at 5,987,928.
IMGN stock has decreased by -24.73% in the last month. The company shares reached their 1-month lowest point of $13.83 on 08/10/23. With the stock rallying to its 52-week high on 07/19/23, shares of the company touched a low of $3.61 and a high of $20.69 in 52 weeks. It has reached a new high 20 times so far this year and achieved 184.07% or $9.13 in price. In spite of this, the price is down -31.90% from the 52-week high.
Insider Transactions
IMGN stock investors should be aware that ImmunoGen Inc. (IMGN) stock had its last reported insider trading activity 7 days ago on Aug 04. In this transaction, the insider spent $16,831,053. SVP & CHIEF BUSINESS OFFICER, Coen Stacy Ann, disposed of 80,326 shares at a price of $17.05 on Aug 04. The insider now owns more than $1,369,558 worth of shares. Prior to that, CHIEF EXECUTIVE OFFICER Enyedy Mark J went on to Sale 1,020,000 shares at $16.61 each on Aug 03. An amount of $16,942,200 was transacted.
Valuation Metrics
ImmunoGen Inc. (IMGN) stock’s beta is 1.02. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 17.98, the price-to-book (PB) ratio at 7.58.
Financial Health
The quick ratio of ImmunoGen Inc. for the three months ended June 29 was 7.10, and the current ratio was 7.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.15 and a total debt to equity ratio of 0.15 for the quarter ending June 29. ImmunoGen Inc.’s EBITDA margin for the year ending June 29 is -201.42%, while its operating margin for the same period stands at -96.80%. Its gross profit as reported stood at $108.61 million compared to revenue of $108.78 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ImmunoGen Inc.’s return on assets was -42.60%.
Earnings Surprise
For the three-month period that ended June 29, ImmunoGen Inc. had $71.96 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$4.25 million in the quarter, while revenues were shrunk -1359.29%. The analyst consensus anticipated ImmunoGen Inc.’s latest quarter earnings to come in at -$0.14 per share, but it turned out to be -$0.02, a 85.70% surprise. For the quarter, EBITDA amounted to -$3.76 million. Shareholders own equity worth $248.94 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at ImmunoGen Inc. (IMGN) price momentum. RSI 9-day as of the close on 10 August was 25.44%, suggesting the stock is oversold, with historical volatility in this time frame at 93.05%.
As of today, IMGN’s price is $14.80 -15.02% or -$2.49 from its 5-day moving average. IMGN is currently trading -25.13% lower than its 20-day SMA and +255.81% higher than its 100-day SMA. However, the stock’s current price level is +4.76% above the SMA50 and +129.48% above the SMA200.
The stochastic %K and %D were 4.27% and 4.45%, respectively, and the average true range (ATR) was 1.01. With the 14-day stochastic at 4.37% and the average true range at 0.98, the RSI (14) stands at 30.68%. The stock has reached -1.78 on the 9-day MACD Oscillator while the 14-day reading was at -2.65.
Analyst Ratings
Piper Sandler upgraded ImmunoGen Inc. (NASDAQ: IMGN) to a an Overweight rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for ImmunoGen Inc. (IMGN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell IMGN, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is IMGN’s price target for the next 12 months?
Analysts predict a range of price targets between $13.00 and $26.00, with a median target of $24.00. Taking a look at these predictions, the average price target given by analysts for ImmunoGen Inc. (IMGN) stock is $22.89.
